
BioInvent, Pfizer sign antibody deal
Executive Summary
BioInvent International AB licensed Pfizer Inc. rights to develop and commercialize antibodies targeting an undisclosed number tumor-associated myeloid cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com